Can-Fite Reports Namodenoson Liver Cirrhosis Case
RAMAT GAN, Israel — September 9, 2026 Can-Fite BioPharma Ltd. announced publication of a peer-reviewed case report describing clinical...
A3 adenosine receptor
Advertisement
Can-Fite Reports Longer Overall Survival in Phase III Liver Cancer Study
RAMAT GAN, Israel, September 2, 2026 Can-Fite BioPharma Ltd. reported that blinded overall survival observed across the entire patient...
Can-Fite BioPharma Reports Namodenoson Pancreatic Cancer Findings
Ramat Gan, Israel — August 17, 2026 Can-Fite BioPharma Ltd. announced new preclinical findings showing that namodenoson enhanced the...
Annexon Expands Phase 3 ARCHER II Trial in Geographic Atrophy
BRISBANE, Calif., August 12, 202 Annexon, Inc. announced the expansion of its ongoing Phase 3 ARCHER II trial evaluating...
LeonaBio Advances Lasofoxifene in Metastatic Breast Cancer
BOTHELL, Wash., August 12, 2026 LeonaBio, Inc. announced that its lead investigational therapy lasofoxifene will be featured in multiple...
Advertisements
Can-Fite Advances Phase III Programs With FDA and EMA Status
RAMAT GAN, Israel, August 12, 2026 Can-Fite BioPharma Ltd. announced an update on the regulatory status of its two...
Can-Fite Phase 2a Namodenoson Pancreatic Cancer Data Accepted at ESMO 2026
RAMAT GAN, Israel, July 20, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that positive Phase 2a clinical trial...
Can-Fite Secures Australian Patent for Namodenoson in Liver and Pancreatic Cancer
Ramat Gan, Israel, July 14, 2026 Can-Fite BioPharma announced that the Australian Patent Office has allowed Patent Application No....
Can-Fite Completes Phase 3 Psoriasis Trial Enrollment
RAMAT GAN, Israel, July 6, 2026 Can-Fite BioPharma announced the completion of enrollment of the first 247 patients in...
Can-Fite Reports Positive Phase 2a Namodenoson Safety Datar
Ramat Gan, Israel, July 1, 2026 Can-Fite BioPharma Ltd. announced that its Phase 2a clinical study evaluating Namodenoson in...
Advertisement
